High-dose ascorbic acid synergizes with anti-PD1 therapy in non-small cell lung cancer <i>in vitro</i> and <i>in vivo</i> models.

ABSTRACT:

Introduction

Immune checkpoint inhibitors(ICIs) targeting programmed cell death protein 1 (PD1) confer significant survival benefits to patients with non-small cell lung cancer (NSCLC). However, there remains a substantial unmet need to identify therapeutic approaches to overcome resistance and provide benefits to these patients. High-dose ascorbic acid (AA) acts synergistically with many standard anticancer treatments. However, little is known about the effect of high-dose AA on improving the efficacy of anti-PD1 inhibitors in NSCLC. This study aimed to elucidate the effects of high-dose AA on anti-PD1 immunotherapy in NSCLC.

Methods

The combined effects of high-dose AA and anti-PD1 were investigated using a coculture model of H460 cells and CD8+ T cells and an LLC1 lung ca

SUBMITTER: Kim HS 

PROVIDER: S-EPMC11783322 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature